NEW YORK, June 7 (GenomeWeb News) - Underwriters of Alnylam Pharmaceuticals' initial public offering have exercised an over-allotment option, the company said today.


The underwriters have purchased an additional 750,000 shares of common stock at the IPO price of $6 per share, less an underwriting discount of $.42 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.